Catalog No.
YMF97801
Expression system
E. coli
Species
Mus musculus (Mouse)
Protein length
Asp74-Ser193
Predicted molecular weight
16.03 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P14404
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Histone-lysine N-methyltransferase MECOM, 2.1.1.367, Ecotropic virus integration site 1 protein, EVI-1, MDS1 and EVI1 complex locus protein, Myelodysplasia syndrome 1 protein homolog, Mecom, Evi1, Mds1, Prdm3
Potential factors underlying the progression of RUNX1-mutated MDS to AML., PMID:40393312
Fate and state transitions during human blood vessel organoid development., PMID:40250419
RUNX1::MECOM rearrangement in myeloid neoplasm post cytotoxic therapy following sarcoma treatment: a case presentation and review of the literature., PMID:40204525
The Fusion Genes and Their Relation with Genetic Variants in Egyptian AML Patients., PMID:40156426
BRPF1 inhibition reduces migration and invasion of metastatic ovarian cancer cells, representing a potential therapeutic target., PMID:40038391
The expression level of EVI1 and clinical features help to distinguish prognostic heterogeneity in the AML entity with EVI1 overexpression., PMID:39956382
Establishment of a high-risk pediatric AML-derived cell line YCU-AML2 with genetic and metabolic vulnerabilities., PMID:39891826
Benzene-induced hematotoxicity enhances the self-renewal ability of HSPCs in Mll-Af9 mice., PMID:39842622
CEBPA repression by MECOM blocks differentiation to drive aggressive leukemias., PMID:39803492
Complex Genetic Evolution and Treatment Challenges in Myeloid Neoplasms: A Case of Persistent t(2;3)(p15~23;q26)/MECOM Rearrangement, SF3B1 Mutation, and Transient TNIP1::PDGFRB Chimera., PMID:39730178
Evi1 governs Kdm6b-mediated histone demethylation to regulate the Laptm4b-driven mTOR pathway in hematopoietic progenitor cells., PMID:39680456
Clinical significance of dynamic monitoring of EVI1 gene expression in pediatric acute myeloid leukemia., PMID:39643863
HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia., PMID:39633068
Systematic pan-cancer analysis of the prognostic value of MECOM in human cancer., PMID:39576394
Protective effect of ginseng extract and total ginsenosides on hematopoietic stem cell damage by inhibiting cell apoptosis and regulating the intestinal microflora., PMID:39513620
MECOM and the PRDM gene family in uterine endometrial cancer: bioinformatics and experimental insights into pathogenesis and therapeutic potentials., PMID:39468462
MECOM Locus classical transcript isoforms affect tumor immune microenvironment and different targets in ovarian cancer., PMID:39427186
Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy., PMID:39383458
[The role and regulation of EVI1 in normal hematopoiesis and hematopoietic malignancies]., PMID:39358295
The microprotein HDSP promotes gastric cancer progression through activating the MECOM-SPINK1-EGFR signaling axis., PMID:39333095
Efficient generation of human NOTCH ligand-expressing haemogenic endothelial cells as infrastructure for in vitro haematopoiesis and lymphopoiesis., PMID:39227582
Modelling and drug targeting of a myeloid neoplasm with atypical 3q26/MECOM rearrangement using patient-specific iPSCs., PMID:39187468
An activity-regulated transcriptional program directly drives synaptogenesis., PMID:39103556
CRISPR-Cas9-mediated deletion enhancer of MECOM play a tumor suppressor role in ovarian cancer., PMID:38995475
Potential molecular and cellular mechanisms of the effects of cuproptosis-related genes in the cardiomyocytes of patients with diabetic heart failure: a bioinformatics analysis., PMID:38883603
IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia., PMID:38841778
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML., PMID:38834613
Evaluation of European LeukemiaNet 2022 risk classification in patients undergoing allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia: Identification of a very poor prognosis genetic group., PMID:38811025
Backtracking NOM1::ETV6 fusion to neonatal pathogenesis of t(7;12) (q36;p13) infant AML., PMID:38806630
Oncogene EVI1 drives acute myeloid leukemia via a targetable interaction with CTBP2., PMID:38748792
Outcome of 3q26.2/MECOM rearrangements in chronic myeloid leukemia., PMID:38748089
Aberrant ecotropic viral integration site-1 (EVI-1) and myocyte enhancer factor 2 C gene (MEF2C) in adult acute myeloid leukemia are associated with adverse t (9:22) & 11q23 rearrangements., PMID:38710877
MECOM: a bioinformatics and experimentally identified marker for the diagnosis and prognosis of lung adenocarcinoma., PMID:38440890
The ETV6-MECOM fusion protein promotes EMT-related properties by repressing the transactivation activity of E-cadherin promoter in K562 leukemia cells., PMID:38405662
Promoter-centred chromatin interactions associated with EVI1 expression in EVI1+3q- myeloid leukaemia cells., PMID:38296260
A novel missense mutation in the MECOM gene in a Chinese boy with radioulnar synostosis with amegakaryocytic thrombocytopenia., PMID:38245683
Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression., PMID:38086946
Copy number variants landscape of multiple cancers and clinical applications based on NGS gene panel., PMID:37967237
[The role of SF3B1 mutations in EVI1-rearranged myeloid neoplasms]., PMID:37914237
Heat shock protein B7 (HSPB7) inhibits lung adenocarcinoma progression by inhibiting glycolysis., PMID:37732539
Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD., PMID:37705244
A novel mutation in MECOM affects MPL regulation in vitro and results in thrombocytopenia and bone marrow failure., PMID:37610030
Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies., PMID:37585491
High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma., PMID:37525239
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents., PMID:37422688
MECOM Deficiency: from Bone Marrow Failure to Impaired B-Cell Development., PMID:37407873
Perinatal-lethal nonimmune fetal hydrops attributed to MECOM-associated bone marrow failure., PMID:37230770
Epigenetic landscape reveals MECOM as an endothelial lineage regulator., PMID:37185814
Fetal hydrops caused by a novel pathogenic MECOM variant., PMID:37160698
Mecom mutation related to radioulnar synostosis with amegakaryocytic thrombocytopenia reduces HSPCs in mice., PMID:37099686
For research use only. Not for human or drug use.
